A B S T R A C T An analysis of prostaglandin-stimulated adenosine 3',5'-cyclic monophosphate (cyclic AMP) accumulation in cultured human umbilical vein endothelial cells showed prostacyclin (PGI2) to be the most potent agonist followed by prostaglandin (PG)H2, which was more potent than PGE2, while PGD2 was essentially inactive.
INTRODUCTION
Prostacyclin [(5Z)-9-deoxy-6,9-a-epoxy-A5-prostaglandin Fi,J (PGI2)1 is a labile prostaglandin that is a Received for publication 13 June 1980 and in revised form 16 October 1980.
'Abbreviations used in this paper: azo analog I, 9,11-azoprosta-5, 13-dienoic acid; 12-HPETE, 12-hydroperoxyeicos-540 potent vasodilator and the most powerful inhibitor of human platelet aggregation yet described (1) (2) (3) (4) . Vascuilar tissue and especially vascular endothelium are rich sources of PGI2 synthetase activity (5-7), and the relationship(s) between the synthesis of the antiaggregatory PGI2 by vascular elements and the synthesis of the proaggregatory molecule thromboxane A2 by platelets have been widely discussed (3, 4, 8, 9) . PGI2 is a potent stimulator of platelet adenylate cyclase (3, 4) , and elevates cyclic AMP levels in ctiltured human foreskin fibroblasts (10) , human fat cell ghosts (11) , and several clonal cell lines of central nervous system origin (12) . PGI2 also elevates cyclic AMP levels in arterial rings (13) , but no experiments on the effect of PGI2 on cyclic AMP levels in endothelial cells have been reported to date.
In the present study we show that PGI2 is a potent stimtulator of cultured human umbilical vein endothelial cell cyclic AMP levels, and suggest that endogenously produced PGI2 may regulate subsequenit PGI2 biosynthesis by stimulating adenylate cyclase.
METHODS
Materials. Prostaglandins (PG) I2, E,, E2, D2, and the prostaglandin analog 9,11 azoprosta-5,13-dienoic acid (azo analog I) were obtained from The Upjohn Company, Kalamazoo, Mich. PGH2 and 12-hydroperoxyeicosatetraenoic acid (12-HPETE) were biosynthesized according to Gorman Radioinznuntoa.ssay of cyclic AMIP. Cyclic ANIP was measured in confluent endothelial cell monolayers -0.8 x 106 cells/35-mm well. Each well was washed once with 2.0 ml of warmed minimlial essential medium (NIEM) containiing 25 miM Hepes buffer (no serum or phenol indicator). The cells were allowed to equilibrate with 1.0 ml of MIEM-Hepes containiing 1.0 mM MIX for 10 min before the addition of agonists. The reactions were terminated by the addition of 0.5 ml of 10% trichloroacetic acid, and the aqueous samples extracted three times with 10 vol of diethylether. Cyclic AMP was measured by radioimmunoassay according to Steiner et al. (16) with the incorporation of the acetylation modification of Harper and Brooker (17) . All samples were tested at two dilutions. Data are presented as the mean±SE M of triplicate determinationis.
Radioimmunoassay of 6-keto PGF la. Thombin-stimulated PGI2 biosynthesis was studied by measuring 6-ketoPGF1a by radioimmunoassay accordinig to Dray et al. (18) .
The antiserum was a gift from Dr. Fernando Dray, The Pasteur Institute, Paris, France. All samples were assayedl at tNwo dilutions. Data are presented as mean+SEM of triplicate determinations. Endothelial cell monolavers were washed once with 2.0 mil of NIENI-Hepes buffer anid allowed to equilibrate with anl additional 1.0 ml of MEM-Hepes for 10 min at 37°C. After the equilibration period, the cells were challenged with 2.0 U of thrombin, and allowed to incubate for an additional 10 mmin at 37°C. The media was then immediately withdrawn anid frozen in liquid N2, and aliquots of the samples were analyzed for 6-keto-PGFlG.
In experiments where PGE, was used to stimulate cyclic AMP levels, all of the samples and standards were assayed before and after alkali treatment. This was done to dehydrate PGEI to PGAI and eliminate PGE, crossreaction with the 6-keto-PGF1,, antiserum. Base treatment was done by adjusting the samples to pH 10.0 with NaHCO3, followed by boiling to dryness. The dried samples were reconstituted with H20 and the pH readjusted to 7.4 for subsequent radioimmunoassay. Authentic 6-keto-PGF1a was degraded <5% by this procedure, whereas PGE, was essentially completely dehydrated to PGA,.
Preparatiotn of particulate fractioni for aden ylate cyclase assay. To eliminate PGI2 biosynthesis during processinig, particulate fractionis were prepared from endothelial cells pretreated for 1 h with 1 miiM acetylsalicvclic acid. Previous experience has shown that this treatmiient inhibits at least 95% of the thrombin-stimulated PGI2 biosynthesis. Cells were harvested with a rubber spatula, and the pooled cells cenitrifuged at 4°C for 15 min at 2,000 x g. The cell pellet was resuspended in cold 50 mM Tris-HCl, 0.15M NaCl buffer, pH 7.50, and frozen and thawed three times in liquid N2, followed by 10 strokes of a Dounce homiiogeniizer (Kontes Co., Vineland, N. J.) (glass/glass). The homiiogeniate was then centrifuged at 10,000 x g for 15 min at 4°C. The resulting pellet was then resuspenided in 1 mMI KHCO3 and used directly in the adenvlate cyclase assaylN.
Adenylvate cyclase activity w,vas meaisured according to Rodbell (19) with m)odificationis as reported by Salomoni et al. (20) , from the rate of formation of cyclic ANIP from [a-32P]ATP. All incubations contaiined 10 mMf theophvlline. Data are presenlted as picomlloles cyclic ANMP per 10 min per milligram protein determined accordinig to Lowry et al. (21) .
Cnlture aIId clharacterizatiotn of enidothelial cells. Endothelial cells were derived from human umbilical cord veins as described b1 Jaffe et al. (22) . Cords were storedl in sterile conitaiiners wvith 20 ml1 of corcl buffer (137 mM\I NaCl, 4 mMI KCI, 10 m\MI Hepes, pH 7.5, and 11 m\M gluicose). A disposable syringe w%las attached to a( blunt needle atnd the vein was flushed with 50 ml of cord buffer to remove aniv blood. The vein was then perfused w.ith 10 mnl of 0.1% collagenase in cord btuffer, and incubated at 37°C in a bath of cord buffer for 10 min. The collageniase-cell miiixtuire was flushed from the vein with 30 ml of buffer into a plastic cenitrifuge tube that contained 10 ml of mnediulm 199 acnd centrifuged at 200 g for 5 min. The cell pellet was resuspended in 10 ml of fresh medium 199 and added to a T-75 flask. Cells were exposed to an atmosphere of 95% air -5% CO2 acnd were fed twice a week until subculturing. Confluenicy was usually reached in 4-5 d.
For subculturing the mediumii was removed and the cells rinsed once with cord buffer. A 5-min incubation with a 1:1 mixture of 0.02% EDTA: 0.2% collagenase followed by centrifugationi was used to harvest the cells. Cells were grown in either T-150 culture flasks or distributed into 35-mmii wells.
Endothelial cells were characterized by (a) the presence of Weibel-Palade bodies as observed by electron microscopy (23) , (b) the ability of the miiediulm from cultured cells to suipport ristocetiin-induced aggltutination of washed humlan platelets (24) , aid (c) b1 immiuniofluorescence studies of Factor VIII acntigein tusinlg a rabbit antibody to human Factor VIII, and a fluioresceini-conijugatedl goat anti-rabbit gammiiiia globulin (25) .
RESULTS
Incubation of intact endothelial cell monolayers with 2.8 ,uM PGI2 resulted in a marked increase in cyclic AMfP within 1 min. The response was maximal at 10 min, and then gradually declined over the next 50 min (Fig. 1) . NIost of the cyclic AMP remained intracellular for at least 60 min (Fig. 1) . We included 1 mM MIX, the cyclic AMP phosphodiesterase inhibitor, in all of our experiments because without MIX there was only a small increase in cyclic AMP in response to PGI2 (Fig. 1) .
Dose-response analysis indicated that PGI2 was a more potent stimulator of endothelial cell cyclic AMP levels than either PGH2 or PGE2, whereas PGD2 was essentially inactive (Fig. 2) . As little as 28 nM PGI2 significanltly elevated cyclic AMP levels above basal levels, and 2.8 pAM PCI2 gave maximnal stimulation (Fig. 2) . This dose-response profile was similar to data previously reported in cultured human foreskin fibroblasts (10) .
Most of the stimulation of cyclic AMP levels in response to PGH2 was shown to be due to conversion of PGH2 to PGI2 by the endothelial cell monolayers. Incu (Fig. 3) . Neither inhibitor significantly changed the basal level of cyclic AMP (Fig. 3) .
As shown previously (26) , endothelial cells also have a ,8-adrenergic receptor that is coupled to the adenylate cyclase. Our data shows that the maximal 18-adrenergic stimulation of cyclic AMP accumulation by Lisoproterenol is considerably less than the stimulation observed with 2.8 ,M PGI2 (Fig. 4) . The isoproterenolstimulation was completely blocked by 10 ,uM propranolol, but propranolol did not inhibit the PGI2-stimulation of cyclic AMP levels (Fig. 4) . (Table I) . Both PGD2 and adenosine were inactive as stimulators of adenylate cyclase (Table I) . Weksler et al. (27) have shown that thrombin stimulates endothelial cell PGI2 biosynthesis. We have found that thrombin-stimulated PGI2 biosynthesis (as measured by 6-keto-PGF,a levels) was attenuated by both PGE1 and L-isoproterenol when the phosphodiesterase was inhibited (Table II) . Neither PGE, nor Lisoproterenol inhibited PGI2 biosynthesis in the absence of phosphodiesterase inhibition (Table II) . The data presented were obtained before and after base treatment (Methods), because PGE, was used to elevate cyclic AMP levels, and PGE1 cross-reacts with the 6-keto-PGFs,,e antibody. Authentic PGI2 could not be used because this would have generated too much exogenous 6-keto-PGF5<, and hampered the subsequent measurement of endogenously synthesized PGI2. Base to 6-keto-PGFse and the synthesis of 6-keto-PGFi, was blocked by 2.8 ,uM azo analog I. This rate of conversion is analogous to previously published data in endothelial cells (7) . treatment of samples hydrolyzes PGE, to PGA,, and PGA, does not interfere with the measurement of 6-keto-PGF1ar (18) . Authentic 6-keto-PGF5, is not degraded by base treatment (Table II) . Of particular interest was the observation that 1.0 mM MIX alone could also reduce thrombin-stimulated PGI2 biosynthesis (Table II) . A combination of PGE, and 1.0 mM MIX inhibited PGI2 biosynthesis 70.0% whereas 1.0 mM MIX inhibited synthesis 38% (Table II) . It should be emphasized that marked elevations in cyclic AMP and inhibition ofthrombin-stimulated PGI2 biosynthesis were observed only when the phosphodiesterase was inhibited.
To assess the possible correlation between cyclic AMP elevation and the inhibition of PGI2 biosynthesis, we measured cyclic AMP levels in endothelial cells exposed to either PGI2 or thrombin with or without 0.1 or 1.0 mM MIX (Table III) . Treatment of the monolayers with 0.1 mM or 1.0 mM MIX increased cyclic AMP levels two-and four-fold, respectively (Table III) . PGI2 or thrombin gave small increases in cyclic AMP without MIX, but 0.1 mM MIX potentiated the PGI2 response to an eight-fold increase, and the thrombin response to a fourfold increase. In the presence of 1.0 mM MIX PGI2 increased cyclic AMP levels 33-fold, and thrombin 12-fold (Table III) .
DISCUSSION
The observation that endothelial cells can synthesize PGI2 from either endogenous or exogenous endoperoxide PGH2 or arachidonic acid (6, 7) has generated a great deal of research concerning endothelial cellplatelet interactions. The thrust of the work has been to assess the influence of PGI2 produced by the endothelium on platelet aggregation and/or adhesion (5-10), but the possible effects of endogenously produced PGI2 on endothelial cell physiology per se have not as yet been explored.
Since PGI2 is a potent stimulator of adenylate cyclase in a variety of cell types (10) (11) (12) we felt it was important to assess the influence of PGI2 on endothelial cell adenylate cyclase as well. PGI2 proved to be a potent stimulator of endothelial cell cyclic AMP accumulation when the cyclic AMP phosphodiesterase was inhibited. This dependence on phosphodiesterase inhibition contrasts sharply with the observed potency in other cultured cell lines (10, 12) , but we have previously observed an analogous high level of cyclic AMP phosphodiesterase activity in isolated arterial rings (13) . The control of endothelial cell sensitivity to PGI2 may be indirectly regulated through the phosphodiesterase, and any agent that suppresses phosphodiesterase activity would enhance the PGI2 response.
In addition to PGI2, exogenously added PGH2 was also readily converted to PGI2 by the endothelial cells resulting in an increase in endothelial cyclic AMP levels. The PGI2 dependence of the PGH2 response was evident by the ability of the prostacyclin synthetase inhibitors 12-HPETE or azo analog I to inhibit most of the PGH2 response. Complete inhibition ofthe PGH2 response is probably not attainable because considerable amounts of PGE2 are synthesized from PGH2 when the PGI2 synthetase is blocked, and PGE2 itself is a weak stimulator of cyclic AMP accumulation. The inhibition of the PGI2 synthetase by 12-HPETE is potentially of in vivo significance. Since 12-HPETE is produced by the platelet (28, 29) , it is possible that platelets interacting with the endothelium could inhibit PGI2 biosynthesis by producing 12 pmol/109 platelets above basal levels, but the platelet is capable of making 6,000-7,000 pmol ofcyclic AMP in response to 2.8 AM PGI2 (30) . Clearly most of the potential responsiveness to PGI2 in the platelet is not expressed. An analogous situation may exist in the endothelial cell.
The precise physiological significance of the PGI2 elevation ofendothelial cell cyclic AMP levels and subsequent inhibition of PGI2 biosynthesis cannot be established by this paper. Previous work has shown that by elevating cyclic AMP, PGI2 can inhibit arachidonic acid transformation in the human platelet (31) . The inhibition by cyclic AMP was at the level of the phospholipase. Our data are consistent with a phospholipase inhibition, but do not rule out inhibition at the level of the cyclooxygenase or the PGI2 synthetase.
We are presently studying PGI2 biosynthesis in endothelial cells to establish exactly at what level(s) biosynthesis is interrupted. Regardless of the exact point of control, it is clear that endothelial biosynthesis of PGI2 is not a passive phenomenon. The cells are responsive to this compound as well.
